Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials

International Journal of Cardiology
Hisato TakagiALICE (All-Literature Investigation of Cardiovascular Evidence) Group

Abstract

Although telmisartan is suggested to improve proteinuria/albuminuria (or prevents progression of proteinuria/albuminuria), conclusive evidence is still lacking. We perform the first meta-analysis of randomized controlled trials of telmisartan therapy on proteinuria/albuminuria. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through February 2012. Eligible studies were prospective randomized controlled trials of telmisartan therapy versus other angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), other anti-hypertensive drug therapy, placebo, or no medication and reporting urinary protein/albumin excretion (UPE/UAE) or urinary protein/albumin to creatinine ratio (UPCR/UACR) levels as an outcome. For each study, data regarding percent changes from baseline to final UPE/UAE/UPCR/UACR levels in both the telmisartan and control groups were used to generate mean differences (MDs) and 95% confidence intervals (CIs). Of 49 potentially relevant articles screened initially, 20 reports of randomized trials enrolling a total of 25,425 patients were included. Pooled analysis suggested a significant reduction in percent changes of UPE/UAE/UPCR/UACR in the 7 ARB-control (MD...Continue Reading

References

Jul 1, 1992·Journal of Clinical Epidemiology·D FollmannJ Cutler
Oct 20, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Haruhito UchidaHirofumi Makino
Nov 2, 2004·The New England Journal of Medicine·Anthony H BarnettUNKNOWN Diabetics Exposed to Telmisartan and Enalapril Study Group
Mar 9, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ming-Cheng WangJeng-Jong Huang
Aug 23, 2005·Diabetes Research and Clinical Practice·Ahmet M SengulLevent Aydin
Oct 7, 2005·Journal of Hypertension·Liffert VogtUNKNOWN Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group
Oct 29, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Emma PrestonEdwina A Brown
Feb 3, 2006·The Journal of Clinical Investigation·Giuseppe RemuzziAndrea Remuzzi
Aug 3, 2006·Kidney International·P A Sarafidis, G L Bakris
Dec 2, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoshi MorimotoKatsunori Sawada
May 3, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jan GalleUNKNOWN VIVALDI investigators
May 23, 2008·Kidney International·George BakrisUNKNOWN AMADEO Study Investigators
Aug 21, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tsukasa NakamuraKoichi Node
Jul 18, 2009·International Heart Journal·Tetsuya NakamuraMasahiko Kurabayashi
Aug 29, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-ichiro MasudaSatoshi Umemura
Jan 30, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Pantelis A SarafidisAnastasios N Lasaridis
Jun 30, 2010·European Journal of Clinical Investigation·Tsukasa NakamuraHikaru Koide
Jul 29, 2010·Kidney & Blood Pressure Research·Kenichiro KinouchiHiroshi Itoh
Jul 16, 2011·The American Journal of the Medical Sciences·Tsukasa NakamuraHikaru Koide
Jul 29, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroshi HasegawaIssei Komuro
Nov 15, 2011·Journal of Hypertension·Cesar CerezoFranz H Messerli

❮ Previous
Next ❯

Citations

Aug 26, 2014·Journal of the American Society of Hypertension : JASH·Hisato TakagiUNKNOWN All-Literature Investigation of Cardiovascular Evidence Group
Mar 5, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Csaba András Dézsi
Mar 7, 2020·Expert Opinion on Pharmacotherapy·Markus WehlandDaniela Grimm
Nov 26, 2019·Basic & Clinical Pharmacology & Toxicology·Juyoung ShinKun-Ho Yoon
Mar 27, 2018·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Juyu CaiDaoqian Shen
Nov 10, 2020·Journal of Veterinary Internal Medicine·Bianca N LourençoKate E Creevy
May 11, 2021·Journal of Veterinary Internal Medicine·Julie LecavalierRomain Javard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.